Valvular Heart Disease Types: Guide & Treatment

Valvular heart disease is not a single diagnosis. It is a taxonomy of stenosis, regurgitation, prolapse, and atresia that determines how blood moves, how chambers remodel, and which specialists need to be in the room. That matters because modern valve practice is being driven by a few dominant phenotypes, including 54.8 million rheumatic heart disease cases, 13.3 million nonrheumatic calcific aortic valve disease cases, and 15.5 million nonrheumatic degenerative mitral valve disease cases worldwide (AHA global analysis).

For hospital leaders, this is more than a classification exercise. A referral labeled aortic stenosis already suggests a likely mechanism, a predictable remodeling pattern, and a treatment pathway that may involve imaging, interventional cardiology, structural heart surgery, anesthesia, and post-procedure surveillance. A program that can't separate lesion type from lesion mechanics will struggle to staff correctly, forecast case mix, or build a coherent valve service line.

Table of Contents

• Why Valve Disease Taxonomy Matters in Modern Programs - Start with the lesion, not the label - The working taxonomy leadership can use

• The Four Valves and Their Signature Lesions - Aortic and mitral valves carry most adult volume - Right-sided valves need the same discipline - What a reader should recognize in seconds

• Stenosis Versus Regurgitation and the Mechanics That Drive Treatment - Pressure overload and volume overload do not remodel the heart the same way - Imaging has to match the mechanics - The dominant lesion drives the treatment question

• Etiologies and the Patient Populations Behind Each Valve Lesion - Degenerative calcification and prolapse are different lesion mechanics - Rheumatic, congenital, and infective causes shape the referral mix - What the referral pattern is really telling the team

• Diagnostic Workup From the Stethoscope to the Cath Lab - MRI and cath fill the gaps when echo does not settle the case - What each test contributes to the valve team

• Treatment Options Across the Modern Structural Heart Toolkit - Match the intervention to the lesion family - Less invasive and transcatheter options widened the toolkit - Prosthetic choices carry their own tradeoffs - The toolkit in practice

• When to Refer and Who Needs to Be on the Team - The referral trigger depends on the lesion - A complete program needs a complete roster - A practical leadership checklist

Why Valve Disease Taxonomy Matters in Modern Programs

The global burden already tells the story. Rheumatic heart disease remains enormous worldwide, while degenerative aortic and mitral disease now dominate many higher-income settings, and the largest increases in age-standardized prevalence of calcific aortic valve disease from 1990 to 2021 occurred in middle and low-middle Socio-demographic Index regions (AHA global analysis). That means valve disease is no longer a niche problem reserved for a few tertiary centers. It has become a broad structural-heart priority that touches population health, capital planning, and workforce design.

Start with the lesion, not the label

A fellow who hears “aortic stenosis” should not stop at the name. The next questions are mechanism, severity, remodeling, and intervention readiness. In older adults, aortic stenosis is usually degenerative calcification, and the physiology is a pressure-overload state that affects the left ventricle in a very different way from a leaky valve (CDC).

That distinction drives staffing. A stenotic lesion often pulls in advanced imaging, invasive hemodynamics, and replacement planning. A regurgitant lesion may demand more nuanced repair assessment, especially when anatomy could support a durable repair rather than replacement.

Practical rule: a valve label tells a program director more than the chamber it involves. It signals the likely pathology, the imaging sequence, and the subspecialists who need to coordinate care.

The working taxonomy leadership can use

The adult taxonomy is straightforward once it is grounded in anatomy. Stenosis means the opening is narrowed. Regurgitation means the valve does not seal and blood leaks backward. Atresia means there is no functional opening at all, a congenital form of obstruction that is anatomically the most severe class (Mayo Clinic, Healthline).

For program planning, that simple taxonomy is the organizing frame. Every later decision, from consult triage to cath lab build-out, starts by asking which of those mechanics is present and which valve carries the problem.

Phenotype	Dominant Valve	Typical Lesion
Calcific narrowing	Aortic	Stenosis
Incomplete closure	Mitral	Regurgitation
Right-sided leakage	Tricuspid	Regurgitation
Congenital absent opening	Pulmonary	Atresia

The Four Valves and Their Signature Lesions

The four valves do not contribute equally to adult practice. In contemporary cohorts, the most common lesions are mitral regurgitation, aortic stenosis, and aortic regurgitation, which is why the aortic and mitral valves dominate structural heart work in many centers (U.S. epidemiology analysis). Tricuspid and pulmonary disease matter too, but they usually enter adult practice with a different referral pattern and a different procedural emphasis.

Aortic and mitral valves carry most adult volume

The aortic valve is the classic site of stenosis in older adults, while aortic regurgitation also appears in adult practice when coaptation fails. The clinical signature is a fixed outflow problem, so the left ventricle works against resistance, not just abnormal flow.

The mitral valve presents differently. Mitral regurgitation is the dominant lesion family, including primary and secondary forms, and it can reflect leaflet disease, annular dilation, or altered ventricular geometry. Mitral stenosis still appears, especially in rheumatic disease, but it is less common in many higher-income programs.

Right-sided valves need the same discipline

The tricuspid valve is the right-sided valve that most often shows up as regurgitation in adult workups. When it leaks, the right atrium and venous system take the hit, and the echo report usually points to annular dilation, leaflet tethering, or structural damage.

The pulmonary valve is less common in routine adult structural work, but its lesion vocabulary still matters. Pulmonary regurgitation is the adult lesion most clinicians encounter, especially in congenital follow-up, while congenital atresia remains the anatomically severe end of the spectrum.

The practical reading habit is simple. If the report says stenosis, the problem is usually forward-flow limitation. If it says regurgitation, the question is how much volume is being forced backward and how the chambers are remodeling around it.

What a reader should recognize in seconds

• Aortic stenosis: narrowed left-sided outflow, often degenerative in older adults.

• Aortic regurgitation: failed aortic closure with backward flow into the left ventricle.

• Mitral regurgitation: backward flow from left ventricle to left atrium.

• Mitral stenosis: narrowed mitral opening, classically linked to rheumatic scarring.

• Tricuspid regurgitation: right-sided leak with systemic venous consequences.

• Pulmonary regurgitation: right ventricular volume burden, often in congenital contexts.

Stenosis Versus Regurgitation and the Mechanics That Drive Treatment

The clearest way to teach valve disease is to separate opening failure from closing failure. Stenosis is a fixed opening problem, so the chamber behind the valve has to generate more pressure to move blood forward. Regurgitation is a closing problem, so blood leaks backward and the chamber on the receiving side carries the extra volume (Cleveland Clinic).

A narrowing valve acts like a tight doorway. The heart can still push blood through it, but only by working harder against resistance. That pressure burden usually leads to concentric hypertrophy, with thicker walls and less reserve for exertion. A leaking valve behaves more like a door that does not shut, so each beat sends some blood the wrong way and the chamber stretches to accommodate the added load.

Pressure overload and volume overload do not remodel the heart the same way

These two mechanics produce different chamber responses. With stenosis, the ventricle faces a fixed obstruction, so pressure rises first and symptoms often appear when the heart can no longer keep up with the workload. That is why severe aortic stenosis usually moves toward intervention once symptoms or high-risk features appear.

Regurgitation follows a different path. The chamber accepts extra volume, then enlarges to handle it, which can hide the severity for a long time. Over time, chronic severe regurgitation can still reduce forward output and lead to heart failure symptoms, so a patient may seem stable until compensation starts to fail (Cleveland Clinic).

Imaging has to match the mechanics

Echo findings should mirror the physiology. Stenosis usually shows restricted leaflet motion and higher transvalvular gradients. Regurgitation requires careful measurement of backward flow and a close look at chamber size and remodeling. The same valve murmur can lead to very different treatment decisions depending on whether the problem is obstruction or leakage.

A dilated chamber does not automatically mean poor pump function, and a preserved ejection fraction does not rule out severe valve disease. The clinician has to connect the lesion type with the chamber response, not stop at the severity label printed on the report.

Severe valve disease is rarely decided by one number. The decision rests on the anatomy, the symptoms, and how the ventricle or atrium is reshaping around the lesion.

The dominant lesion drives the treatment question

• Stenosis: fixed obstruction, rising pressure, and a higher gradient across the valve.

• Regurgitation: backward flow, volume overload, and progressive chamber dilation.

• Mixed lesions: both mechanics may be present, so the dominant lesion has to be identified first.

• Functional regurgitation: the valve leaflets may be structurally intact, but annular dilation or chamber distortion still produces leakage.

For a structural heart program, that distinction does more than sharpen wording. It points the team toward the right intervention pathway, the right imaging questions, and the right mix of specialists, from interventional cardiology and cardiac imaging to surgery and, in some cases, congenital expertise.

Etiologies and the Patient Populations Behind Each Valve Lesion

Etiology tells a structural heart program what kind of patients will walk through the door, and which valve problems are likely to dominate the schedule. Degenerative calcification usually points toward older adults and aortic stenosis. Rheumatic disease points toward patients with prior untreated streptococcal infection and a different pattern of mitral and aortic involvement, as reflected in public health summaries from the CDC and the AHA global analysis. Congenital malformation shifts the age profile completely, while infective endocarditis and degenerative prolapse change both urgency and repair strategy.

Degenerative calcification and prolapse are different lesion mechanics

Degenerative calcification is the classic substrate for aortic stenosis in older adults. The leaflets thicken, stiffen, and lose their opening motion, so the dominant problem is fixed obstruction rather than a congenital defect or a primarily leaking valve. That distinction is laid out in the Mayo Clinic overview of valve disease causes and symptoms.

Degenerative prolapse works through a different mechanism. The leaflets become stretched and floppy, then bow backward into the atrium or outflow chamber, which usually produces regurgitation instead of narrowing, a pattern also described in Healthline. That difference matters for the program's staffing model. Prolapse often raises repair questions and favors imaging precision, while calcific stenosis more often pushes the team toward replacement planning.

Rheumatic, congenital, and infective causes shape the referral mix

Rheumatic scarring can deform more than one valve and can involve the valve apparatus in a way that is more anatomically tangled than isolated degenerative disease. For a program, that means referrals with a different surgical map, more multivalve overlap, and a need for close coordination between imaging, intervention, and surgery. The same burden also helps explain why rheumatic disease still matters in global valve services, as summarized in the AHA global analysis.

Congenital malformations bring a different age group and a different set of questions. Atresia is the clearest example, because no functional opening exists and blood flow is blocked by a solid tissue sheet, with pulmonary valve atresia often used as the familiar congenital example in clinical descriptions from Healthline. These referrals often require congenital expertise rather than the standard adult-only pathway.

Infective endocarditis changes the pace of care. It can destroy leaflets and chordal support quickly, so a lesion that began as valve disease may present as abrupt, severe regurgitation. That pattern shifts the program from routine planning to urgent multidisciplinary review, because the anatomy can change from one study to the next.

What the referral pattern is really telling the team

Older adults with calcific aortic stenosis usually need a pathway built around degenerative obstruction and replacement planning. Rheumatic mitral disease in a younger or globally diverse cohort points toward more complex reconstruction and surgical input. Congenital valve referrals call for coordination with pediatric or adult congenital expertise. Endocarditis-related destruction demands fast decision-making across specialties. Prolapse-heavy mitral referrals place more weight on repair assessment, careful imaging, and a team that can separate leaflet redundancy from simple chamber dilation.

The lesion mechanism matters, but so does the population behind it. That is the taxonomy a structural heart program has to know when staffing the right mix of imaging, intervention, surgery, and congenital support.

Diagnostic Workup From the Stethoscope to the Cath Lab

A careful valve workup still starts at the bedside. The first murmur a clinician hears often points toward the dominant mechanism, stenosis or regurgitation, before any imaging is ordered. Timing, radiation, and the response to maneuvers help narrow the lesion pattern, and that early read matters because the next test should answer a specific question, not just add another image.

A sharp systolic murmur at the base, a holosystolic murmur at the apex, or a diastolic murmur along the left sternal border each pushes the team toward a different valve and a different mechanism. The exam does not replace imaging, but it tells the structural heart team where to look first.

The electrocardiogram and chest imaging help show the physiologic footprint of the valve lesion. Rhythm disturbance, chamber strain, enlargement, or pulmonary congestion can support the bedside impression, while biomarkers can add context when symptoms and anatomy do not line up cleanly. None of those tests define valve anatomy on their own.

Echocardiography remains the workhorse because it answers the questions that matter most. It shows which valve is involved, how severe the lesion is, and what the chambers and ventricular function are doing in response. For a closer look at reading the study in that sequence, this echocardiogram interpretation guide is a useful reference point.

MRI and cath fill the gaps when echo does not settle the case

Cardiac MRI is useful when the team needs better quantification of regurgitation or a clearer look at myocardial tissue. It also helps assess ventricular remodeling, especially when echo windows are limited or the severity of the lesion is still uncertain after standard imaging.

Cardiac catheterization comes later, after noninvasive imaging has left a real question or when intervention is already being planned. In a mature valve program, cath is a targeted tool for hemodynamics, coronary assessment, and procedural planning. It is not used just to repeat what echo already showed.

The sequence is usually straightforward, bedside suspicion, echo for anatomy and hemodynamics, MRI when quantification remains unclear, and cath when unanswered questions affect treatment.

What each test contributes to the valve team

• Stethoscope and exam: identify the likely lesion pattern.

• ECG and chest imaging: show physiologic impact, not valve anatomy.

• Echocardiography: define lesion type and severity.

• Cardiac MRI: refine regurgitation quantification and myocardial assessment.

• Cardiac catheterization: settle hemodynamic questions before treatment.

Treatment Options Across the Modern Structural Heart Toolkit

Valve treatment starts with the lesion mechanics. Stenosis means the valve is too tight, so the main job is to relieve obstruction. Regurgitation means the valve leaks, so the goal is to restore one-way flow if the anatomy allows it. Atresia is a different problem, because there is no usable opening to work through, so treatment planning follows a separate path from the acquired lesions that dominate adult structural heart work. Medical therapy can steady symptoms, but it cannot fix a valve that is severely narrowed or significantly incompetent.

Match the intervention to the lesion family

Medical management still matters, even when it does not correct the valve itself. Rate control can help when a fast rhythm worsens filling, afterload reduction can lower the burden in selected regurgitant states, and anticoagulation is required when rhythm or prosthetic-valve factors make it appropriate. The regimen depends on the lesion, the rhythm, and the patient's procedural history. For teams building a shared workflow around thromboembolic risk and valve choice, anticoagulation therapy guidelines are part of the same conversation.

Surgical repair is the preferred anatomic solution when native tissue can be preserved. That is especially true in selected mitral and tricuspid regurgitant lesions, where restoring leaflet coaptation can keep the patient's own valve architecture in place. Surgical replacement is used when the valve is too damaged to repair, and the choice between mechanical and bioprosthetic valves depends on age, tolerance for anticoagulation, and the durability the patient will need over time.

A resident learning valve taxonomy should connect the operation to the defect, not to the label alone.

Less invasive and transcatheter options widened the toolkit

Balloon valvuloplasty still has a place in selected stenotic lesions. It works best when the anatomy is favorable and the team needs temporary relief of obstruction or a catheter-based option instead of open surgery. TAVR is the main transcatheter strategy for aortic stenosis, and it has changed how structural programs staff, image, and coordinate care.

Transcatheter edge-to-edge repair is the percutaneous repair concept used for selected regurgitant lesions when leaflet approximation is possible. It now sits at the center of many mitral and tricuspid discussions, especially for patients who are poor surgical candidates or whose anatomy can be treated without opening the chest. In practice, it gives the team another way to match therapy to mechanism.

Prosthetic choices carry their own tradeoffs

Once a valve is replaced, the lesion is no longer the only issue. Prosthetic valves introduce questions about durability, follow-up, and anticoagulation, so the heart team has to think beyond the implant itself. Mechanical valves usually offer long service life, but they bring anticoagulation implications. Bioprosthetic valves avoid lifelong anticoagulation in many patients, while creating a different set of longevity tradeoffs.

That difference affects staffing and follow-up as much as it affects procedure selection.

The toolkit in practice

• Stenosis: balloon valvuloplasty in selected cases, surgical replacement, or transcatheter replacement when anatomy and risk profile fit.

• Regurgitation: surgical repair when feasible, replacement when repair will not last, TEER in selected anatomy.

• Atresia: specialized congenital planning and device or surgical strategies based on whether a channel can be created or reconstructed.

• Prosthetic considerations: mechanical valves bring durability with anticoagulation implications, while bioprosthetic valves avoid lifelong anticoagulation in many patients but have different longevity tradeoffs.

When to Refer and Who Needs to Be on the Team

Referral should begin before a patient looks unstable. Symptom onset, ejection fraction decline, pulmonary hypertension, and progressive chamber dilation are the changes that should move a patient out of surveillance and into specialist review, especially when the valve lesion is already severe or likely to progress. A valve program that waits for overt failure has already lost the best timing window.

A useful way to sort referral is by lesion mechanics. Pressure overload from stenosis, volume overload from regurgitation, and absent or incomplete valve opening in atresia each create a different pattern of risk, so the trigger for action is not the same in every patient.

The referral trigger depends on the lesion

A patient with stenosis and new exertional symptoms needs prompt structural assessment because the obstruction is no longer being compensated. The narrowed valve works like a fixed bottleneck, so the ventricle has to generate more force just to maintain flow. A patient with regurgitation and enlarging chambers needs follow-up before forward output falls and remodeling becomes harder to reverse. Here the valve behaves like a leaky one-way door, and the ventricle gradually pays the price of the backflow. That is where lesion type and timing intersect.

A complete program needs a complete roster

A functional valve service line requires noninvasive cardiologists to recognize lesions early, structural heart interventionalists to judge catheter-based options, cardiac surgeons to repair or replace when anatomy demands it, and advanced heart failure expertise when ventricular dysfunction or volume overload is advanced. It also needs advanced practice providers and valve coordinators, because valve care breaks down when scheduling, education, and follow-up are fragmented. A clear cardiac surgeon job description helps hospitals define who should own operative planning, perioperative judgment, and surgical rescue when a catheter plan is not enough.

The staffing question is practical, not abstract. A hospital that sees more calcific aortic stenosis needs replacement expertise and imaging depth. A referral stream that skews toward complex regurgitation needs repair judgment, transcatheter planning, and close coordination with surgical colleagues.

A strong valve program does not just treat disease. It organizes the right people around the right lesion at the right time.

A practical leadership checklist

• Symptomatic severe lesions: refer without delay.

• Falling ejection fraction: involve a valve team early.

• Pulmonary hypertension: reassess severity and procedural timing.

• Progressive dilation: do not wait for irreversible remodeling.

• Mixed or unclear lesions: escalate to multidisciplinary review.

Hospitals that need to build or strengthen a valve program should treat staffing as a clinical strategy, not a human resources afterthought. American Cardiology Group works with hospitals and health systems that need cardiology and cardiac surgery talent aligned to structural heart demand, from subspecialty recruitment to hard-to-fill clinical roles. Visit American Cardiology Group to connect the right specialists to the valve service line your patients and program require.